WE
HUMA icon

Wealth Effects’s Humacyte HUMA Stock Holding History

Wealth Effects’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$542K Buy
693,920
+489,420
+239% +$454K 0.15% 122
2026
Q1 		$124K Buy
204,500
+51,433
+34% +$53.5K 0.04% 227
2025
Q4 		$147K Sell
153,067
-54,950
-26% -$77.8K 0.05% 210
2025
Q3 		$362K Buy
208,017
+105,850
+104% +$207K 0.12% 137
2025
Q2 		$214K Buy
102,167
+5,600
+6% +$10.8K 0.08% 188
2025
Q1 		$165K Sell
96,567
-24,833
-20% -$93.2K 0.07% 186
2024
Q4 		$613K Buy
121,400
+57,200
+89% +$283K 0.22% 90
2024
Q3 		$349K Buy
+64,200
New +$423K 0.12% 144

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Wealth Effects's HUMA Position: Q2 2026 in Review

Wealth Effects increased its Humacyte (HUMA) stake by 239% in Q2 2026, buying an estimated $454K and bringing the position to 693,920 shares worth $542K. The position accounts for 0.15% of the portfolio, ranked #122.

Wealth Effects first reported a position in HUMA in Q3 2024 and has held it in 8 quarters since. The position peaked at $613K in Q4 2024. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Wealth Effects held 693,920 shares of Humacyte worth $542K as of Q2 2026.
  • Wealth Effects bought 489,420 Humacyte shares in Q2 2026, an estimated $454K.
  • Humacyte made up 0.15% of Wealth Effects's portfolio in Q2 2026, its #122 holding.
  • Wealth Effects first reported a position in Humacyte in Q3 2024 and has held it in 8 quarters since.
  • Wealth Effects's Humacyte position peaked at $613K in Q4 2024.
  • 161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Wealth Effects's 13F filing for Q2 2026, filed 6 Aug 2026.